ArticleFrontiers in oncology2026
The chromosomal instability associated gene C2orf76 exerts dual roles in colorectal cancer through pyroptosis and chemotherapy response.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite advances in colorectal cancer (CRC) treatment, the chromosomal instability (CIN)-positive subgroup remains refractory to conventional therapies and immunotherapy. C2orf76, a poorly characterized gene identified as a CIN-linked candidate in CRC through bioinformatic analyses, has been associated with favorable prognosis and potential immune-related functions. However, its biological roles and underlying mechanisms in CRC remain largely unexplored. Methods: To investigate the role of C2orf76, we generated knockout (KO), overexpression (OE), and rescue (RE) cell lines in CRC models. We performed RNA-seq, RT-qPCR, and Western blotting to examine transcriptomic and protein-level changes. Functional assays included proliferation, migration, cisplatin sensitivity, pyroptosis (GSDME cleavage), cytokinesis-block micronucleus assay (CBMN) for CIN, and γ-H2AX foci detection for DNA double-strand breaks. Results: Unexpectedly, C2orf76 KO suppressed proliferation and migration, contradicting its favorable prognostic association and suggesting a complex regulatory role. RNA-seq revealed altered genes involved in chromosome segregation, cell cycle, platinum resistance, P53 signaling, and oncogenic pathways. RT-qPCR validated changes in chromosomal stability-related genes CDT1 and FOXM1, which were further verified by Western blotting. Further experiments showed that KO inhibited cisplatin-induced pyroptosis and cleavage of GSDME, whereas OE promoted migration and enhanced cisplatin sensitivity. The CBMN assay confirmed that C2orf76 significantly impacts chromosomal instability levels in CRC cells. C2orf76 KO cells also exhibited elevated γ-H2AX foci after cisplatin treatment. Rescue of C2orf76 expression reversed the KO-induced suppression of proliferation and migration, restored cisplatin sensitivity and pyroptosis, and reduced chromosomal instability. Discussion: These findings unveil a context-dependent duality of C2orf76: knockout increases CIN, reduces proliferation and migration, but promotes chemoresistance; overexpression enhances cisplatin-induced pyroptosis and drug sensitivity yet increases migration. Thus, C2orf76 establishes a functional link between CIN, cell death, and therapeutic response, positioning it as a tunable target that may require context-dependent modulation for effective CRC intervention. This study not only characterizes a previously understudied gene but also provides a mechanistic framework for understanding how CIN-associated genes can exert opposing effects on tumor progression and treatment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.